Filing Overview
This Form 8-K was filed by Anzu Special Acquisition Corp I, not Envoy Medical, Inc. The report concerns events occurring on October 1, 2022 and was signed on October 4, 2022. It reports corporate governance and management appointments under Item 5.02.
Business Context and Reporting Period
Anzu Special Acquisition Corp I was a Delaware special purpose acquisition company with securities listed on Nasdaq under the symbols ANZUU, ANZU, and ANZUW. The filing does not describe Envoy Medical’s operating business or provide financial-period results.
Key Financial Metrics
- Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics: not provided in this filing.
- No financial statements or updated financial guidance are included.
Material Changes
- The board increased from three directors to five directors.
- Daniel J. Hirsch and Diane L. Dewbrey were appointed as directors, effective immediately.
- Hirsch was appointed Chief Financial Officer and Corporate Secretary.
- Dewbrey was designated an independent director under Nasdaq standards and appointed to the Audit, Compensation, Nominating and Corporate Governance, and special committees. She also became chair of the Compensation Committee.
- The sponsor transferred 25,000 shares of Class B common stock to each of Hirsch and Dewbrey.
Outlook, Risks, and Unusual Items
- The filing provides no business outlook, financial guidance, or management forecast.
- The appointments may affect governance, financial reporting oversight, and management responsibilities, but no operational or financial impact is quantified.
- An indemnification agreement and letter agreement were entered into with each appointee in substantially the same form used for existing officers and directors.
- The filing states that neither appointee nor members of their immediate families had a reportable related-party transaction under Item 404(a) of Regulation S-K.
Investor Verification Items
- Verify the issuer identity: the supplied filing is for Anzu Special Acquisition Corp I, while the request metadata identifies Envoy Medical, Inc.
- Confirm the final board composition, committee memberships, and executive officer responsibilities.
- Review subsequent filings for the effect of the Class B share transfers and any later business combination or transaction developments.
- Check subsequent periodic filings for financial results, liquidity, sponsor arrangements, and redemption or business-combination risks, none of which are addressed here.